This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nitroaspirin
Accession Number
DB12445  (DB05822)
Type
Small Molecule
Groups
Investigational
Description

Nitroaspirin has been investigated for the treatment of Intermittent Claudication.

Structure
Thumb
Synonyms
Not Available
External IDs
NCX 4016 / NCX-4016
Categories
UNII
EH04H13L6B
CAS number
175033-36-0
Weight
Average: 331.28
Monoisotopic: 331.069201763
Chemical Formula
C16H13NO7
InChI Key
IOJUJUOXKXMJNF-UHFFFAOYSA-N
InChI
InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3
IUPAC Name
3-[(nitrooxy)methyl]phenyl 2-(acetyloxy)benzoate
SMILES
CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 5-androstenedione.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Nitroaspirin.Approved, Investigational
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Nitroaspirin.Approved
AcebutololNitroaspirin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Nitroaspirin.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNitroaspirin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Nitroaspirin.Approved, Vet Approved
AclarubicinNitroaspirin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nitroaspirin.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinNitroaspirin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alendronic acid.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nitroaspirin.Approved, Investigational
AliskirenNitroaspirin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Nitroaspirin.Approved, Illicit, Investigational
AlprenololNitroaspirin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Nitroaspirin.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alteplase.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nitroaspirin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Amcinonide.Approved
AmikacinNitroaspirin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNitroaspirin may decrease the antihypertensive activities of Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Nitroaspirin.Illicit, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aminosalicylic Acid.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nitroaspirin.Approved
Ammonium chlorideThe serum concentration of Nitroaspirin can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Nitroaspirin.Approved
AmrubicinNitroaspirin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Nitroaspirin.Approved
AncrodNitroaspirin may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Nitroaspirin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nitroaspirin.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Anistreplase.Approved
AnnamycinNitroaspirin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nitroaspirin.Approved
Antithrombin III humanNitroaspirin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apocynin.Investigational
ApramycinNitroaspirin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Nitroaspirin.Approved, Investigational
AprotininThe therapeutic efficacy of Nitroaspirin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArbekacinNitroaspirin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNitroaspirin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Nitroaspirin.Approved, Investigational
ArotinololNitroaspirin may decrease the antihypertensive activities of Arotinolol.Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Atamestane.Investigational
AtenololNitroaspirin may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Nitroaspirin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Nitroaspirin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nitroaspirin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitroaspirin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Batroxobin.Experimental
BecaplerminNitroaspirin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNitroaspirin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNitroaspirin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bemiparin.Approved, Investigational
BenazeprilNitroaspirin may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nitroaspirin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nitroaspirin.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Benzydamine.Approved
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Nitroaspirin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Betamethasone.Approved, Vet Approved
BetaxololNitroaspirin may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nitroaspirin.Approved, Investigational
BevantololNitroaspirin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nitroaspirin.Approved, Investigational
BisoprololNitroaspirin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNitroaspirin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Nitroaspirin can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BopindololNitroaspirin may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nitroaspirin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Nitroaspirin.Investigational
BucindololNitroaspirin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bufexamac.Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Nitroaspirin.Experimental
BufuralolNitroaspirin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bumadizone.Experimental
BumetanideNitroaspirin may decrease the diuretic activities of Bumetanide.Approved
BupranololNitroaspirin may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Nitroaspirin.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Nitroaspirin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nitroaspirin.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nitroaspirin.Approved
CandoxatrilNitroaspirin may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Nitroaspirin.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Caplacizumab.Investigational
CaptoprilNitroaspirin may decrease the antihypertensive activities of Captopril.Approved
CarbamazepineThe metabolism of Nitroaspirin can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nitroaspirin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nitroaspirin.Approved, Vet Approved, Withdrawn
CarteololNitroaspirin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNitroaspirin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nitroaspirin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nitroaspirin.Approved, Investigational
CeliprololNitroaspirin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNitroaspirin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nitroaspirin.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nitroaspirin.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Nitroaspirin.Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nitroaspirin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nitroaspirin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ciclesonide.Approved, Investigational
CilazaprilNitroaspirin may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Nitroaspirin.Approved
CinoxacinNitroaspirin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidNitroaspirin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nitroaspirin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Nitroaspirin.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Nitroaspirin.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Nitroaspirin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nitroaspirin.Vet Approved
CloranololNitroaspirin may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Nitroaspirin.Experimental
ClorindioneNitroaspirin may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Nitroaspirin.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Nitroaspirin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nitroaspirin.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nitroaspirin.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nitroaspirin.Approved, Investigational, Vet Approved
Dabigatran etexilateNitroaspirin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNitroaspirin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNitroaspirin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanNitroaspirin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nitroaspirin.Approved, Investigational
DaunorubicinNitroaspirin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Nitroaspirin.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deflazacort.Approved, Investigational
DelaprilNitroaspirin may decrease the antihypertensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Nitroaspirin.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dersalazine.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Nitroaspirin.Approved
DesirudinNitroaspirin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexketoprofen.Approved, Investigational
DextranNitroaspirin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nitroaspirin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nitroaspirin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nitroaspirin may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNitroaspirin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Nitroaspirin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nitroaspirin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diclofenamide.Approved
DicoumarolNitroaspirin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Nitroaspirin.Approved, Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nitroaspirin.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nitroaspirin.Approved
DihydrostreptomycinNitroaspirin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nitroaspirin.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nitroaspirin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nitroaspirin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nitroaspirin.Approved
DiphenadioneNitroaspirin may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nitroaspirin.Approved
DitazoleThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Nitroaspirin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Nitroaspirin.Approved
DoxorubicinNitroaspirin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNitroaspirin may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Nitroaspirin.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Nitroaspirin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Nitroaspirin.Investigational
Edetic AcidNitroaspirin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNitroaspirin may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilNitroaspirin may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatNitroaspirin may decrease the antihypertensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Nitroaspirin.Approved, Investigational
EnoxacinNitroaspirin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNitroaspirin may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nitroaspirin.Experimental
EpanololNitroaspirin may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Nitroaspirin.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Nitroaspirin.Approved
EpirubicinNitroaspirin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNitroaspirin may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Nitroaspirin.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Nitroaspirin.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitroaspirin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nitroaspirin.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Nitroaspirin.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Equilin.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Nitroaspirin.Investigational
EsmololNitroaspirin may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nitroaspirin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Nitroaspirin.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Nitroaspirin.Approved
EstroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Nitroaspirin.Approved
Etacrynic acidNitroaspirin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nitroaspirin.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nitroaspirin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateNitroaspirin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Nitroaspirin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Nitroaspirin.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nitroaspirin.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Nitroaspirin.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Nitroaspirin.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Nitroaspirin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Nitroaspirin.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Nitroaspirin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nitroaspirin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nitroaspirin.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Feprazone.Experimental
Ferulic acidNitroaspirin may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitroaspirin.Approved, Investigational
FleroxacinNitroaspirin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nitroaspirin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fludrocortisone.Approved
FluindioneNitroaspirin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNitroaspirin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Nitroaspirin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nitroaspirin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nitroaspirin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nitroaspirin.Approved, Nutraceutical, Vet Approved
FondaparinuxNitroaspirin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNitroaspirin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nitroaspirin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilNitroaspirin may decrease the antihypertensive activities of Fosinopril.Approved
FramycetinNitroaspirin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNitroaspirin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNitroaspirin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNitroaspirin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GarlicThe serum concentration of Nitroaspirin can be decreased when it is combined with Garlic.Approved
GatifloxacinNitroaspirin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nitroaspirin.Approved, Withdrawn
GemifloxacinNitroaspirin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNitroaspirin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNitroaspirin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANitroaspirin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Nitroaspirin.Approved, Investigational, Nutraceutical
GlucosamineGlucosamine may increase the antiplatelet activities of Nitroaspirin.Approved
GPX-150Nitroaspirin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNitroaspirin may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nitroaspirin is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hemoglobin crosfumaril.Experimental
HeparinNitroaspirin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Nitroaspirin.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nitroaspirin.Approved, Investigational
HydralazineNitroaspirin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nitroaspirin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nitroaspirin.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Nitroaspirin.Investigational
Hygromycin BNitroaspirin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nitroaspirin.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Nitroaspirin.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nitroaspirin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Nitroaspirin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Nitroaspirin.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Nitroaspirin.Approved, Nutraceutical
IdarubicinNitroaspirin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNitroaspirin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Nitroaspirin.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Nitroaspirin.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitroaspirin.Approved, Investigational
ImidaprilNitroaspirin may decrease the antihypertensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nitroaspirin.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nitroaspirin.Approved
IndenololNitroaspirin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nitroaspirin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Nitroaspirin.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Nitroaspirin.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nitroaspirin.Approved, Investigational
IsepamicinNitroaspirin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nitroaspirin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Istaroxime.Investigational
KanamycinNitroaspirin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Nitroaspirin.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Nitroaspirin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nitroaspirin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nitroaspirin.Approved
LabetalolNitroaspirin may decrease the antihypertensive activities of Labetalol.Approved
LandiololNitroaspirin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nitroaspirin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nitroaspirin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nitroaspirin.Approved, Investigational
LepirudinNitroaspirin may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNitroaspirin may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNitroaspirin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNitroaspirin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nitroaspirin.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Nitroaspirin.Experimental
LisinoprilNitroaspirin may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Nitroaspirin.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nitroaspirin.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Nitroaspirin.Experimental
LonazolacThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Nitroaspirin.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroaspirin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nitroaspirin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nitroaspirin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nitroaspirin.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nitroaspirin.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nitroaspirin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nitroaspirin.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nitroaspirin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Nitroaspirin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nitroaspirin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nitroaspirin.Approved
MelagatranNitroaspirin may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nitroaspirin.Approved, Vet Approved
MepindololNitroaspirin may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Nitroaspirin.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Nitroaspirin.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Nitroaspirin.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nitroaspirin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nitroaspirin.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Nitroaspirin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNitroaspirin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nitroaspirin.Approved
MetoprololNitroaspirin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNitroaspirin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinNitroaspirin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nitroaspirin.Approved, Illicit
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Nitroaspirin.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Nitroaspirin.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nitroaspirin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mizoribine.Investigational
MoexiprilNitroaspirin may decrease the antihypertensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nitroaspirin.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nitroaspirin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nitroaspirin.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Nitroaspirin.Approved
NadololNitroaspirin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNitroaspirin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNitroaspirin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitroaspirin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Nitroaspirin.Investigational
Nalidixic AcidNitroaspirin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nitroaspirin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Nitroaspirin is combined with NCX 1022.Investigational
NeamineNitroaspirin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNitroaspirin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Nitroaspirin.Approved, Withdrawn
NemonoxacinNitroaspirin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNitroaspirin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nitroaspirin.Approved
NetilmicinNitroaspirin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nitroaspirin.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nitroaspirin.Approved, Investigational, Withdrawn
NorfloxacinNitroaspirin may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Nitroaspirin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Obinutuzumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroaspirin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nitroaspirin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Nitroaspirin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatNitroaspirin may decrease the antihypertensive activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nitroaspirin.Approved, Nutraceutical
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Nitroaspirin.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Nitroaspirin.Vet Approved
OtamixabanNitroaspirin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nitroaspirin.Approved
Oxolinic acidNitroaspirin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNitroaspirin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nitroaspirin.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ozagrel.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Nitroaspirin.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Parnaparin.Approved, Investigational
ParomomycinNitroaspirin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Parthenolide.Investigational
PazufloxacinNitroaspirin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNitroaspirin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNitroaspirin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNitroaspirin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nitroaspirin.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nitroaspirin.Approved, Investigational
PerindoprilNitroaspirin may decrease the antihypertensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pethidine.Approved
PhenindioneNitroaspirin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNitroaspirin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nitroaspirin.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Nitroaspirin.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nitroaspirin.Approved, Investigational
PindololNitroaspirin may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidNitroaspirin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNitroaspirin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNitroaspirin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nitroaspirin.Approved, Investigational
Piromidic acidNitroaspirin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nitroaspirin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pirprofen.Experimental
Platelet Activating FactorNitroaspirin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNitroaspirin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNitroaspirin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nitroaspirin.Approved
PractololNitroaspirin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nitroaspirin.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Nitroaspirin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Nitroaspirin.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Nitroaspirin.Approved, Investigational
PropranololNitroaspirin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nitroaspirin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nitroaspirin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nitroaspirin.Vet Approved
Protein CNitroaspirin may increase the anticoagulant activities of Protein C.Approved
Protein S humanNitroaspirin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNitroaspirin may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Nitroaspirin.Approved
PrulifloxacinNitroaspirin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Nitroaspirin.Investigational
PuromycinNitroaspirin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilNitroaspirin may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nitroaspirin.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Nitroaspirin.Investigational
RamiprilNitroaspirin may decrease the antihypertensive activities of Ramipril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Nitroaspirin.Investigational
RescinnamineNitroaspirin may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nitroaspirin.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Reteplase.Approved
ReviparinNitroaspirin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNitroaspirin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Nitroaspirin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Rimexolone.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Nitroaspirin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Risedronate.Approved, Investigational
RivaroxabanNitroaspirin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Nitroaspirin.Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Rosiglitazone.Approved, Investigational
RosoxacinNitroaspirin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nitroaspirin.Approved
RufloxacinNitroaspirin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNitroaspirin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nitroaspirin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nitroaspirin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nitroaspirin.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nitroaspirin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nitroaspirin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Nitroaspirin.Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Nitroaspirin.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Saruplase.Experimental
SelexipagThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Nitroaspirin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Nitroaspirin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitroaspirin.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nitroaspirin.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nitroaspirin.Approved
SisomicinNitroaspirin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNitroaspirin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Nitroaspirin.Approved
SotalolNitroaspirin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNitroaspirin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNitroaspirin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNitroaspirin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilNitroaspirin may decrease the antihypertensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Nitroaspirin.Investigational
St. John's WortThe metabolism of Nitroaspirin can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Streptokinase.Approved, Investigational
StreptomycinNitroaspirin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNitroaspirin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nitroaspirin.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nitroaspirin.Approved
SulodexideNitroaspirin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nitroaspirin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nitroaspirin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Nitroaspirin.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nitroaspirin.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nitroaspirin.Approved
TalinololNitroaspirin may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nitroaspirin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Nitroaspirin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nitroaspirin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nitroaspirin.Approved, Investigational
TemafloxacinNitroaspirin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilNitroaspirin may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Temsirolimus.Approved
TenecteplaseThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nitroaspirin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Nitroaspirin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Nitroaspirin.Approved
TertatololNitroaspirin may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Nitroaspirin.Investigational
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Nitroaspirin.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nitroaspirin.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Nitroaspirin.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNitroaspirin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tinzaparin.Approved
TioclomarolNitroaspirin may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Nitroaspirin.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Nitroaspirin.Approved
TixocortolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tixocortol.Approved, Withdrawn
TobramycinNitroaspirin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Nitroaspirin.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nitroaspirin.Approved
TorasemideNitroaspirin may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tositumomab.Approved, Investigational
TrandolaprilNitroaspirin may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Nitroaspirin.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Nitroaspirin.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nitroaspirin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nitroaspirin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNitroaspirin may decrease the antihypertensive activities of Triamterene.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Nitroaspirin.Approved
TribenosideThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nitroaspirin.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Nitroaspirin.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Nitroaspirin.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Nitroaspirin.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Trolamine salicylate.Approved
TrovafloxacinNitroaspirin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNitroaspirin may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nitroaspirin.Approved, Investigational
UrokinaseNitroaspirin may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nitroaspirin.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Nitroaspirin.Approved, Investigational
ValrubicinNitroaspirin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroaspirin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nitroaspirin.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nitroaspirin.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Nitroaspirin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nitroaspirin.Approved
WarfarinNitroaspirin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNitroaspirin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nitroaspirin.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nitroaspirin.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nitroaspirin.Approved, Investigational, Withdrawn
ZofenoprilNitroaspirin may decrease the antihypertensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nitroaspirin.Withdrawn
Zoptarelin doxorubicinNitroaspirin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNitroaspirin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W: NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Int J Oncol. 2003 Jun;22(6):1297-302. [PubMed:12738997]
  2. Fiorucci S, Del Soldato P: NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis. 2003 May;35 Suppl 2:S9-19. [PubMed:12846439]
External Links
PubChem Compound
119032
PubChem Substance
347828686
ChemSpider
106359
ChEBI
125482
ChEMBL
CHEMBL374385

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentIntermittent Claudication1
2TerminatedPreventionEarly Nephropathy / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00402 mg/mLALOGPS
logP3.04ALOGPS
logP3.17ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)-6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area104.97 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity81.5 m3·mol-1ChemAxon
Polarizability31.6 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Depsides and depsidones
Sub Class
Not Available
Direct Parent
Depsides and depsidones
Alternative Parents
Acylsalicylic acids and derivatives / Phenol esters / Benzoic acid esters / Phenoxy compounds / Benzoyl derivatives / Dicarboxylic acids and derivatives / Alkyl nitrates / Organic nitro compounds / Organic nitric acids and derivatives / Carboxylic acid esters
show 4 more
Substituents
Depside backbone / Acylsalicylic acid or derivatives / Benzoate ester / Phenol ester / Benzoic acid or derivatives / Phenoxy compound / Benzoyl / Monocyclic benzene moiety / Benzenoid / Dicarboxylic acid or derivatives
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Gresele P, Momi S: Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev. 2006 Summer;24(2):148-68. [PubMed:16961726]

Drug created on October 20, 2016 16:25 / Updated on December 01, 2017 16:30